PEC Ltd. US$160 million buyout and privatization by Liberty Energy Solutions Ltd
SINGAPORE, May 7, 2025 /PRNewswire/ -- PEC Ltd ("PEC", SGX: IX2) shareholders have approved a transaction valued at US$160 million for the 100% acquisition by Alliance Energy Services Pte Ltd ("Alliance") through a Scheme of Arrangement at...
TIER IV fuels development of autonomous driving standards and an open dataset in Japanese government initiative
TOKYO, May 7, 2025 /PRNewswire/ -- TIER IV, the pioneering force behind the world's first open-source software for autonomous driving, is proud to announce its selection for a major Japanese government project aimed at expanding deployments of...
SGS & Co and SGK unite to become Propelis – a global agency built for brand impact
Propelis family of brands created to serve wide range of client needs across the globe, with the packaging graphics and print solutions teams from SGS & Co and SGK combining into SGX CHICAGO, May 7, 2025 /PRNewswire/ -- Two of the world's most...
Lake Resources Announces Exploration of Strategic Alternatives
SYDNEY, May 7, 2025 /PRNewswire/ -- Lake Resources N.L. (ASX: LKE; OTC: LLKKF) ("Lake" or the "Company"), a responsible lithium developer, announced today that its Board of Directors will form a Special Committee composed of all members of the Board...
FancyTech Closes Series B+ to Power AI Personalized Content Solutions in Thailand and Southeast Asia
BANGKOK, May 7, 2025 /PRNewswire/ -- FancyTech, an AI startup specializing in commercial content generation and winner of the 2024 LVMH Innovation Award, has announced the successful close of its Series B+ funding round. The round was co-led by GSR...
Successful Extension of Nucleic Acid Aptamer Pharmacokinetics in Joint Research by Ajinomoto Co., Inc. and RIBOMIC Inc.
AJICAP® Antibody-Drug Conjugate Manufacturing Technology Contributes to Enhanced Efficacy of Antibody Drugs TOKYO, May 7, 2025 /PRNewswire/ -- Ajinomoto Co., Inc. (President: Shigeo Nakamura, Headquarters: Chuo-ku, Tokyo, hereinafter referred to as...
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 7, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011...
Bispecific vs. Bispecific: Innovent Announces First Patient Dosed in the Phase 2 Clinical Study of Efdamrofusp Alfa (IBI302), a First-in-class Anti-VEGF and Anti-Complement Bispecific Fusion Protein for the Treatment of Diabetic Macular Edema
SAN FRANCISCO and SUZHOU, China, May 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of...